Dyadic International, Inc.

NASDAQ:DYAI

Biotechnology

Healthcare
$1.47 +21.49%

+$0.26 today

Market cap
$53.56M
Beta
1.15
P/E (TTM)
-6.9
EPS (TTM)
-$0.20
52W Low $0.65High $1.55

Volume 0.71M

Average 0.31M

DYAI EBITDA Margin

EBITDA as a percentage of revenue.

Dyadic International, Inc.NASDAQ: DYAI

EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026

EBITDA Margin widens to -166.1%

EBITDA Margin was -166.1% in Q1 FY2026, up 872.8 pp from a year earlier. On a trailing-twelve-month basis it was -230.3%, down 71.7 pp year over year. Over 3 fiscal years it narrowed by 215.4 pp.

Context

  • EBITDA Margin widened in 2 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of -100.0% for the fiscal year ending Dec 2026, up from -560.6% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterMar 2026
-166.1%+442.5 pp QoQ
Last fiscal yearDec 2025
-560.6%-406.7 pp YoY
LTMMar 2026
-230.3%-71.7 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+872.8 pp+262.5 pp-610.3 pp
1 year-406.7 pp+460.6 pp+867.3 pp
3 years-215.4 pp+460.6 pp+676.1 pp
5 years——
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-560.6%
Year-over-year change
-406.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How DYAI compares with its peers on the latest reported figures

  • DYAI's LTM Mar 2026 EBITDA Margin of -230.3% is the highest of the 4 companies compared; the peer median is -292.4%.
  • Its year-over-year change of -71.7 pp is the 3rd highest of 4, against a peer median of +217.9 pp.
  • Over three fiscal years its change of -215.4 pp compares with a peer median of +275.1 pp.
DYAI Competitors Peer median
EBITDA Margin for DYAI and competitors
Company Period LTM level YoY 3-year change
DYAIDyadic International, Inc.LTM Mar 2026-230.3% -71.7 pp-215.4 pp
ATHEAlterity Therapeutics LimitedFY2025-269.0% +217.9 pp+70.4 pp
CELUCelularity Inc.LTM Dec 2025-292.4% -215.5 pp+479.8 pp
RNXTRenovoRx, Inc.LTM Mar 2026-823.9% +2311.5 pp—
MAIAMAIA Biotechnology, Inc.FY2025— ——
PYPDPolyPid Ltd.FY2025— ——
VERUVeru Inc.FY2025— ——
ANVSAnnovis Bio, Inc.FY2025— ——
Peer median (excluding DYAI) -292.4%+217.9 pp+275.1 pp

Competitors are the stored peer set for DYAI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue2.4M2.93M2.9M3.5M1.23M
Cost of Revenue1.94M2.12M1.98M1.19M2.32M
Gross Profit459.39K807.11K922.96K2.3M(1.09M)
Gross Margin19.1%27.5%31.8%65.8%-88.3%
Research & Development8.39M4.5M3.3M2.04M2.15M
Selling, General & Admin6.7M6.42M5.82M6.13M5.76M
Operating Expenses15.19M10.97M9.15M8.2M6.06M
Depreciation & Amortization3.49M038.42K00
EBITDA(11.14M)(10.12M)(8.15M)(5.38M)(6.91M)
EBITDA Margin-463.4%-345.2%-281.3%-154.0%-560.6%
Operating Income(14.73M)(10.17M)(8.23M)(5.9M)(7.15M)
Operating Margin-612.7%-346.9%-283.9%-168.8%-579.9%
Interest Income51.7K180.42K416.69K456.99K284.09K
Interest Expense000427.97K455.9K
Other Income / Expenses1.66M430.42K1.43M91.66K(218.71K)
Income Before Tax(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Pre-Tax Margin-543.7%-332.2%-234.4%-166.2%-597.6%
Income Tax Expense00000
Net Income(13.07M)(9.74M)(6.8M)(5.81M)(7.36M)
Net Margin-543.7%-332.2%-234.4%-166.2%-597.6%
EPS (Basic)(0.47)(0.34)(0.24)(0.20)(0.23)
EPS (Diluted)(0.47)(0.34)(0.24)(0.20)(0.23)
Weighted Avg Shares27.84M28.36M28.8M29.32M32.62M
Weighted Avg Shares (Diluted)27.84M28.36M28.8M29.32M32.62M

Dyadic International, Inc.

NASDAQ:DYAI

Intrinsic Alpha fair value

Locked

Current Price

$1.47

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.